Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 生活保健科技系 > 期刊論文 > Item 310902800/34697

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34697

標題:	Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
作者:	Chung, Mu-Chi Hsu, Hui-Tsung Chang, Chao-Hsiang Hung, Peir-Haur Hsiao, Po-Jen Wu, Laing-You Wu, Ming-Ju Shieh, Jeng-Jer Chung, Chi-Jung
貢獻者:	Taichung Veterans General Hospital National Chung Hsing University National Chung Hsing University Asia University Taiwan China Medical University Taiwan China Medical University Taiwan China Medical University Hospital - Taiwan Chia-Yi Christian Hospital Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science National Chung Hsing University Taichung Veterans General Hospital China Medical University Taiwan China Medical University Hospital - Taiwan
關鍵字:	cardiovascular outcomes empagliflozin metaanalysis mortality cancer
日期:	2022
上傳時間:	2023-12-11 14:05:42 (UTC+8)
出版者:	NATURE PORTFOLIO
摘要:	Sodium-glucose cotransporter 2 inhibitor (SGLT2i) potentially decrease all-cause and cardiovascular death, however, associations with non-cardiovascular death remain unclear. Therefore, we investigated SGLT2i associations with death and the cause of death. We used the Taiwanese National Health Institutes Research database linked to the National Register of Deaths (NRD). Incident type 2 diabetes mellitus (T2DM) patients and propensity score matched T2DM SGLT2i and Dipeptidyl peptidase 4 inhibitor (DPP4i) users were investigated. The index year was the SGLT2i or DPP4i prescription date from May 2016. Patients were followed-up until death or December 2018. Deaths verified by the NRD and grouped accordingly. Multiple Cox proportional hazards models were used. In total, 261,211 patients were included in the population; 47% of the patients were female and the average age was 62 years. The overall incidence of all-cause death was 8.67/1000 patient-years for SGLT2i and 12.41 for DPP4i users during follow-up. After adjusting for potential risk factors in the propensity score matched population, SGLT2i users were associated with lower risks of all-cause death, cardiovascular death, cancer death, and non-cancer, non-vascular death compared with DPP4i-users. For specific death causes, significantly lower death risks from heart disease, cerebrovascular disease, and accidents were associated with SGLT2i-use. SGLT2i benefits for T2DM patients were not different across subgroups. Compared with DPP4i-use, SGLT2i-use for T2DM was associated with lower disease and death risk.
關聯:	SCIENTIFIC REPORTS, v.12, n.10147
顯示於類別:	[生活保健科技系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	252	檢視/開啟
s41598-022-13760-7.pdf		1234Kb	Adobe PDF	140	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....